• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Renovacor Inc. (Amendment)

    1/19/22 3:20:25 PM ET
    $RCOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RCOR alert in real time by email
    SC 13G/A 1 tm223894d1_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Amendment No. 1)*

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO §240.13d-2

     

    Renovacor, Inc. f/k/a Chardan Healthcare Acquisition 2 Corp.
    (Name of Issuer)

     

    Common Stock, $0.0001 par value
    (Title of Class of Securities)

     

    75989E106
    (CUSIP Number)

     

    January 18, 2022
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1 (b)

     

      x Rule 13d-1 (c)

     

      ¨ Rule 13d-1 (d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

       


    1

    NAME OF REPORTING PERSON
    South Ocean Capital Management

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨
    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION
    Florida

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER
    575,000

     

    6

    SHARED VOTING POWER
    -0-

     

    7

    SOLE DISPOSITIVE POWER
    575,000

     

    8

    SHARED DISPOSITIVE POWER
    -0-

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    575,000

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    3.33%

     

    12

    TYPE OF REPORTING PERSON*
    CO

     

           

      

     

     

     

      


    1

    NAME OF REPORTING PERSON
    Steven M. Oliveira

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨
    (b) x

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S.A.

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5

    SOLE VOTING POWER
    -0-

     

    6

    SHARED VOTING POWER
    -0-

     

    7

    SOLE DISPOSITIVE POWER
    -0-

     

    8

    SHARED DISPOSITIVE POWER
    -0-

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    -0-

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    0%

     

    12

    TYPE OF REPORTING PERSON*
    OO

     

           

      

     

     

       

    Item 1.

     

      (a) Name of Issuer: Renovacor, Inc. f/k/a Chardan Healthcare 2 Acquisition Corp.

     

      (b) Address of Issuer's Principal Executive Offices:

    P.O. Box 8142

    Greenwich, CT 0683

     

    Item 2.

     

      (a) Name of Person Filing:

    South Ocean Capital Management, LLC

    Steven M. Oliveira

     

      (b) Address of Principal Business Office or if none, Residence:

     

    South Ocean Capital Management, LLC:

    South Ocean Capital Management, LLC

    225 Via Palacio

    Palm Beach Gardens, FL 33418

     

    Steven Oliveira:

    c/o South Ocean Capital Management, LLC

    225 Via Palacio

    Palm Beach Gardens, FL 33418

     

      (c) Citizenship: South Ocean Capital Management, LLC – Florida

    Steven M. Oliveira – U.S.A.

     

      (d) Title of Class of Securities:  Common Stock, $0.0001 par value

     

      (e) CUSIP Number: 75989E106

     

    Item 3. Not Applicable

     

    Item 4. Ownership.

     

      (a) Amount Beneficially Owned:

     

    South Ocean Capital Management, LLC – 575,000 shares.

     

    Steven Oliveira – 0 shares.

     

    Steven Oliveira has voting and dispositive power over the securities owned by South Ocean Capital Management, LLC.

     

      (b) Percent of Class:

     

    South Ocean Capital Management – 3.33%

     

    Steven Oliveira – 0%

     

     

     

     

      (c) Number of shares as to which such person has:

     

      (i) sole power to vote or to direct the vote:

     

    South Ocean Capital Management, LLC – 575,000 shares.

     

    Steven Oliveira – 0 shares.

     

      (ii) shared power to vote or to direct the vote:

     

    South Ocean Capital Management, LLC – 0 shares.

     

    Steven Oliveira – 0 shares.

     

      (iii) sole power to dispose or to direct the disposition of:

     

    South Ocean Capital Management, LLC – 575,000 shares.

     

    Steven Oliveira – 0 shares.

     

      (iv) shared power to dispose or to direct the disposition of:

     

    South Ocean Capital Management, LLC – 0 shares.

     

    Steven Oliveira – 0 shares.

     

    Item 5.

    Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial  owner of more than five percent of the class of securities, check the following  x.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person: Not Applicable

     

    Item 7. Identification and Classification of Subsidiary Which Acquired the Securities: Not Applicable

     

    Item 8. Identification and Classification of Members of the Group: Not Applicable

     

    Item 9. Notice of Dissolution of Group: Not Applicable

     

    Item 10. Certifications: Not Applicable

     

     

     

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    January 19, 2022

      

      SOUTH OCEAN CAPITAL MANAGEMENT, LLC
           
           
      By: /s/ Steven Oliveira  
        Name:  Steven Oliveira  
        Title:    Authorized Signatory  
           
           
        /s/ Steven Oliveira  
        Steven Oliveira  

     

     

     

     

     

     

    Get the next $RCOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RCOR

    DatePrice TargetRatingAnalyst
    9/13/2022$9.00Outperform
    Robert W. Baird
    10/14/2021$22.00Buy
    Ladenburg Thalmann
    10/1/2021$20.00Buy
    Chardan Capital Markets
    More analyst ratings

    $RCOR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Renovacor Inc.

      15-12G - Renovacor, Inc. (0001799850) (Filer)

      12/12/22 4:35:37 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Renovacor Inc.

      EFFECT - Renovacor, Inc. (0001799850) (Filer)

      12/6/22 12:15:05 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Renovacor Inc.

      EFFECT - Renovacor, Inc. (0001799850) (Filer)

      12/6/22 12:15:13 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $RCOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $RCOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $RCOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

      Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

      10/17/23 6:00:00 AM ET
      $BDN
      $RMTI
      $RCOR
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Completes Acquisition of Renovacor

      Acquisition further extends Rocket's leadership in AAV-based cardiac gene therapy and expands focus and capabilities to BAG3-associated dilated cardiomyopathy Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that it has completed the previously announced acquisition of Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. Under the terms of t

      12/1/22 4:01:00 PM ET
      $RCKT
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy

      Acquisition further strengthens Rocket's leadership in AAV-based cardiac gene therapy and expands Company's near-term clinical assets for the treatment of heart conditions Significant unmet medical need in BAG3-associated dilated cardiomyopathy, with meaningful commercial opportunity, comparable to Danon Disease Creates strong synergies by combining key assets, personnel, capabilities and IP, as well as access to world-leading scientific and clinical collaborators, expected to deliver long-term value for Rocket and Renovacor shareholders We believe compelling preclinical data generated by Renovacor validates mechanism of action of AAV-based transgene replacement strategy for BAG-3 di

      9/20/22 6:00:00 AM ET
      $RCKT
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Renovacor Inc. (Amendment)

      SC 13D/A - Renovacor, Inc. (0001799850) (Subject)

      4/5/23 4:31:54 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Renovacor Inc. (Amendment)

      SC 13G/A - Renovacor, Inc. (0001799850) (Subject)

      2/14/23 7:41:31 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Renovacor Inc.

      SC 13D - Renovacor, Inc. (0001799850) (Subject)

      9/21/22 9:00:09 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Renovacor with a new price target

      Robert W. Baird initiated coverage of Renovacor with a rating of Outperform and set a new price target of $9.00

      9/13/22 7:37:19 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on Renovacor with a new price target

      Ladenburg Thalmann initiated coverage of Renovacor with a rating of Buy and set a new price target of $22.00

      10/14/21 7:14:33 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets initiated coverage on Renovacor with a new price target

      Chardan Capital Markets initiated coverage of Renovacor with a rating of Buy and set a new price target of $20.00

      10/1/21 7:39:25 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Rtw Investments, Lp

      4 - Renovacor, Inc. (0001799850) (Issuer)

      4/5/23 4:30:43 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Needham Thomas E. Jr.

      4 - Renovacor, Inc. (0001799850) (Issuer)

      12/5/22 9:24:00 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Lau Joan

      4 - Renovacor, Inc. (0001799850) (Issuer)

      12/5/22 9:23:45 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    Leadership Updates

    Live Leadership Updates

    See more
    • Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

      Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

      10/17/23 6:00:00 AM ET
      $BDN
      $RMTI
      $RCOR
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovacor Announces the Appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations

      Dr. Dhanasekharan joins Renovacor with extensive experience overseeing development, manufacturing and supply operations for biologics including AAV gene therapies Renovacor, Inc. (NYSE:RCOR), a biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations. "With Kumar's appointment, we've added yet another innovative industry expert to Renovacor's diverse and growing leadership team," said Magdalene Cook, M.D., Chief Executive Officer of Renovacor. "Kumar is

      10/4/21 4:05:00 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovacor Announces the Appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science

      Dr. Shin to help advance REN-001 into the clinic by leveraging nearly two decades of expertise in clinical development, academic research and medical practice Renovacor, Inc. (NYSE:RCOR), an early-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science. "We are excited to welcome Jordan to Renovacor's leadership team during this pivotal time for the company," said Magdalene Cook, M.D., Chief Executive Officer of Renovacor.

      9/22/21 4:05:00 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care